Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096009639> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- W3096009639 endingPage "24" @default.
- W3096009639 startingPage "24" @default.
- W3096009639 abstract "Introduction The D-dimer (DD) assay represents a major biological test for the diagnosis and monitoring of thrombotic conditions. DD testing is usually not performed as part of the routine laboratory management of patients with hemophilia (PWH). There is an increasing concern about the risk of thrombotic complications in PWH, whether related to age, the presence of cardiovascular risk factors, invasive thrombogenic procedures, over-correction of FVIII or FIX, or the administration of new therapeutic agents in particular rebalancing agents such as TFPI-inhibiting molecules or Fitusiran. Arterial and venous thrombotic events have indeed recently been reported in PWH treated with these agents. It is therefore important to have simple, easily accessible biological tests available to detect and monitor the development of any prothrombotic condition in PWH with these agents and at increased risk of thrombosis. Baseline DD concentrations in PWH have not been extensively studied yet. Patients and methods We prospectively measured over a 18 months period the DD level in all consecutive PWH with hemophilia A (PWHA) in routine clinics outside bleeding episode, invasive procedure or acute medical or surgical problems. A total of 65 adult PWHA (17-76 yr) with severe (58) to moderate (n=7) disease without inhibitor on replacement therapy with FVIII were included. CRP, fibrinogen, FVIII and VWF levels were also measured at time of DD assay. Results Thirty-three patients had not measurable DD (< 250 ng/ml), 15 had levels below 500 ng/ml, 10 had levels between 500-1000 ng/ml and 7 > 1000 ng/ml. Age>70 (3), smoking (7), arterial vascular disease (2), liver cancer (2) could explain DD > 500 ng/ml in 15/17 patients. Conclusions Most PWHA on replacement therapy with FVIII had low or unmeasurable DD levels. The reasons for high DD level in PWHA do not differ from the general population. In most PWAH, the DD assay could be a useful tool to detect prothrombotic state, potentially related to hemophilia therapies. Disclosures Hermans: Bayer:Consultancy, Research Funding, Speakers Bureau;Pfizer:Consultancy, Research Funding, Speakers Bureau;Shire, a Takeda company:Consultancy, Research Funding, Speakers Bureau;Sobi:Consultancy, Research Funding, Speakers Bureau;Biogen:Consultancy, Speakers Bureau;CAF-DCF:Consultancy, Speakers Bureau;CSL Behring:Consultancy, Speakers Bureau;LFB:Consultancy, Speakers Bureau;Novo Nordisk:Consultancy, Speakers Bureau;Roche:Consultancy, Speakers Bureau;Octapharma:Consultancy, Speakers Bureau;Kedrion:Speakers Bureau;EAHAD:Other;WFH:Other." @default.
- W3096009639 created "2020-11-09" @default.
- W3096009639 creator A5008435049 @default.
- W3096009639 creator A5051513022 @default.
- W3096009639 date "2020-11-05" @default.
- W3096009639 modified "2023-09-30" @default.
- W3096009639 title "Potential Usefulness of D-Dimers Assay in Treated Patients with FVIII Deficiency to Detect a Prothrombotic State" @default.
- W3096009639 doi "https://doi.org/10.1182/blood-2020-137517" @default.
- W3096009639 hasPublicationYear "2020" @default.
- W3096009639 type Work @default.
- W3096009639 sameAs 3096009639 @default.
- W3096009639 citedByCount "0" @default.
- W3096009639 crossrefType "journal-article" @default.
- W3096009639 hasAuthorship W3096009639A5008435049 @default.
- W3096009639 hasAuthorship W3096009639A5051513022 @default.
- W3096009639 hasConcept C126322002 @default.
- W3096009639 hasConcept C141071460 @default.
- W3096009639 hasConcept C187212893 @default.
- W3096009639 hasConcept C2778959117 @default.
- W3096009639 hasConcept C2779036427 @default.
- W3096009639 hasConcept C2779519742 @default.
- W3096009639 hasConcept C2780868729 @default.
- W3096009639 hasConcept C71924100 @default.
- W3096009639 hasConcept C90924648 @default.
- W3096009639 hasConceptScore W3096009639C126322002 @default.
- W3096009639 hasConceptScore W3096009639C141071460 @default.
- W3096009639 hasConceptScore W3096009639C187212893 @default.
- W3096009639 hasConceptScore W3096009639C2778959117 @default.
- W3096009639 hasConceptScore W3096009639C2779036427 @default.
- W3096009639 hasConceptScore W3096009639C2779519742 @default.
- W3096009639 hasConceptScore W3096009639C2780868729 @default.
- W3096009639 hasConceptScore W3096009639C71924100 @default.
- W3096009639 hasConceptScore W3096009639C90924648 @default.
- W3096009639 hasIssue "Supplement 1" @default.
- W3096009639 hasLocation W30960096391 @default.
- W3096009639 hasOpenAccess W3096009639 @default.
- W3096009639 hasPrimaryLocation W30960096391 @default.
- W3096009639 hasRelatedWork W2044336004 @default.
- W3096009639 hasRelatedWork W2357380556 @default.
- W3096009639 hasRelatedWork W2371807296 @default.
- W3096009639 hasRelatedWork W2374962473 @default.
- W3096009639 hasRelatedWork W2382871238 @default.
- W3096009639 hasRelatedWork W2460966854 @default.
- W3096009639 hasRelatedWork W2735562885 @default.
- W3096009639 hasRelatedWork W3025917752 @default.
- W3096009639 hasRelatedWork W3032069692 @default.
- W3096009639 hasRelatedWork W4315927077 @default.
- W3096009639 hasVolume "136" @default.
- W3096009639 isParatext "false" @default.
- W3096009639 isRetracted "false" @default.
- W3096009639 magId "3096009639" @default.
- W3096009639 workType "article" @default.